Live Breaking News & Updates on Pneumococcal

Stay updated with breaking news from Pneumococcal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Pfizer Inc.: Pfizer Announces Positive Top-Line Results from Phase 3 Study in 20-Valent Pneumococcal Conjugate Vaccine in Infants in the European Union

Positive pivotal top-line data demonstrates 20-valent pneumococcal conjugate vaccine candidate (20vPnC), if approved, can likely help protect against all 20 vaccine serotypes in three-dose series ....

Annaliesa Anderson , Pediatric Program , Exchange Commission , European Commission Decision , European Medicines Agency , Vaccine Research , Senior Vice President , Chief Scientific Officer , Pnc Phase , Breakthroughs That Change Patient , Pfizer News , Annual Report , Looking Information , Factors That May Affect Future Results ,

Merck & Co., Inc.: Merck Receives Positive CHMP Opinion for VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) in Infants and Children

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the ....

United States , Julie Cunningham , Alexis Constantine , Kimberly Petrillo , Peter Dannenbaum , Eliav Barr , Merck Research Laboratories , European Commission , Drug Administration , Statement Of Merck Co Inc , Exchange Commission , Merck Co Inc , European Union , European Medicines Agency , Medicinal Products , Human Use , Conjugate Vaccine , Merck Research , Safety Information , Pneumococcal Disease , Looking Statement , Securities Litigation Reform Act , Annual Report , Prescribing Information , Medication Guide ,

Pfizer: Phase 3 Study Of 20-Valent Pneumococcal Conjugate Vaccine Posts Positive Results In Infants

NEW YORK CITY (dpa-AFX) - Drug major Pfizer Inc. (PFE) announced Friday positive top-line results from its pivotal U.S. Phase 3 study (NCT04382326) evaluating its 20-valent pneumococcal conjugate ....

Pfizer Inc , Drug Administration , More Such Health News , Biologics License Application , Therapy Designation , Fast Track Designation ,

PCV13 pneumococcal vaccine reduces risk of acute chest syndrome in kids with sickle cell anemia: JAMA

France: Implementing a 13-valent pneumococcal conjugate vaccine (PCV13) in the general pediatric population may reduce the incidence of acute chest syndrome (ACS) in children with sickle-cell disease. ....

Basse Normandie , Zein Assad , Acute Chest Syndrome , Valent Pneumococcal Conjugate Vaccine , Acute Chest Syndrome , Sickle Cell Disease , Pneumococcal Conjugate Vaccine , Streptococcus Pneumonia ,

FDA Approves Merck's Vaxneuvance For Prevention Of Invasive Pneumococcal Disease In Children

KENILWORTH (NJ) (dpa-AFX) - The U.S. Food and Drug Administration has approved an expanded indication for Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) to include children 6 weeks through ....

Merck Co Inc , Us Centers For Disease , Drug Administration , Prevention Advisory Committee On Immunization Practices , Conjugate Vaccine , Disease Control , Advisory Committee , Immunization Practices ,